Accession Number:



Operation Brain Trauma Therapy

Descriptive Note:

Technical Report,30 Sep 2010,29 Sep 2016

Corporate Author:

University of Pittsburgh Pittsburgh United States

Personal Author(s):

Report Date:


Pagination or Media Count:



Operation brain trauma therapy OBTT is a groundbreaking, rigorous, multicenter pre-clinical drug and biomarker screening consortium for traumatic brain injury TBI. It is supported by2 closely linked grants from DoD, i.e., WH81XWH-10-1-0623 and OBTT extended studies WH81XWH-14. As requested, this final report is restricted to work on the parent OBTT grant WH81XWH-10-1-0623. OBTT features testing in rat TBI models at the Univ. of Pittsburgh, the Univ. of Miami, and WRAIR, in a micro pig model at Virginia Commonwealth Univ., and biomarker studies at Banyan Biomarkers, Univ. of Florida, and Messina Univ. This grant supported testing of 8drugs. Screening carried out in 1200 rats included standard outcomes and 5000 biomarker samples. Levetiracetam showed the most benefit in 2 models. Glibenclamide and amantadine showed model dependent benefit in contusion and penetrating brain injury. The biomarker GFAP performed well. OBTT produced 86 deliverables, including a full issue of J Neurotrauma. The biomarker data were well-received by FDA. OBTT is recognized as a pioneer in the TBI field.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement: